Overview
- Editors:
-
-
Franco M. Muggia
-
New York University Medical Center, New York, USA
-
Charles W. Young
-
Memorial Sloan-Kettering Cancer Center, New York, USA
-
Stephen K. Carter
-
Northern California Oncology Group, Palo Alto, USA
Access this book
Other ways to access
Table of contents (51 papers)
-
-
Biological Effects
-
-
-
-
- J. Westendorf, Hildegard Marquardt, Hans Marquardt
Pages 30-49
-
-
Mechanism of Action
-
-
-
- F. Arcamone, E. Arlandini, M. Menozzi, L. Valentini, E. Vannini
Pages 74-85
-
- K. W. Kohn, L. A. Zwelling
Pages 86-96
-
-
- M. Robert-Nicoud, N. Bachur
Pages 103-116
-
- A. W. Prestayko, V. H. DuVernay, B. H. Long, S. T. Crooke
Pages 117-124
-
- H. S. Schwartz, P. M. Kanter, A. J. Marinello, H. L. Gurtoo
Pages 125-131
-
- C. Peterson, C. Paul, G. Gahrton, S. Vitols, M. Rudling
Pages 132-146
-
-
- M. E. Scheulen, H. Muliawan, H. Kappus
Pages 159-164
-
-
Drug Development
-
Front Matter
Pages 173-173
-
About this book
F. M. MUGGIA When faced with the inadequacies of current cancer treatment, we prefer to look at what the future may hold. Quite often, we take for granted the past, preferring research into totally new areas. However, the persistent development of fertile soil may yield surprising rewards for those who choose to build on the knowledge of the past--hence, this symposium on anthracycline antibiotics. Although the anthracycline antibiotics represent much of the present and future of cancer treatment, their actual use c stretches back barely two decades to the pioneering efforts of Aurelio Di Marco, who characterized the antitumor properties of daunomycin and adriamycin. * The clinical application of these two compounds heralded a decade of excitement among oncologists dealing with pediatric tumors, breast cancer, leukemias, and lymphomas, and opened new hope for patients afflicted with sar comas and a variety of other tumors that had been deemed - sistant to chemotherapy. These successes were tempered with the realization that the antitumor effect of anthracyclines could be achieved at times only at the very high price of risking cardiac decompensation and, almost invariably, with the occurrence of alopecia and other acute toxicities. This record of past achievements and problems has slowly given way to a present increasingly illuminated by our ability to modify the distressing toxicities of these agents. Detailed clinical studies supplemented by ingenious laboratory models have gradually elucidated mechanisms and risk factors im plicated in the cardiomyopathy.
Editors and Affiliations
-
New York University Medical Center, New York, USA
Franco M. Muggia
-
Memorial Sloan-Kettering Cancer Center, New York, USA
Charles W. Young
-
Northern California Oncology Group, Palo Alto, USA
Stephen K. Carter
